Clinical Research Directory
Browse clinical research sites, groups, and studies.
EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy
Sponsor: University of Texas Southwestern Medical Center
Summary
Proton pump inhibitors (PPIs) are widely used for the control of gastric ulcer-gastritis, erosive esophagitis (gastroesophageal reflux disease), peptic ulcer disease (duodenal ulcer), and heartburn. Despite their efficacy, their use has been implicated in possibly causing fragility fractures (osteoporosis), hypomagnesemia (magnesium deficiency) and increased risk of chronic kidney disease (CKD). The current trial represents the investigators ongoing effort to discern whether these complications could be averted by effervescent calcium magnesium citrate (EffCaMgCit).
Official title: Effervescent Calcium Magnesium Citrate to Prevent Mineral Metabolism and Renal Complications of Chronic Proton Pump Inhibitor Therapy
Key Details
Gender
All
Age Range
21 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
56
Start Date
2024-04-19
Completion Date
2026-12-31
Last Updated
2025-05-23
Healthy Volunteers
Yes
Conditions
Interventions
EffCaMgCit
Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
Placebo
Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate.
Locations (2)
University of Texas Southwestern Medical Center
Dallas, Texas, United States
UT Southwestern Medical Center
Dallas, Texas, United States